| Efalizumab in the treatment of psoriasis. | |
| | |
MedLine Citation:
|
PMID: 15379774 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Efalizumab is a humanized, monoclonal antibody, which targets CD11a, one of the subunits of leukocyte function-associated antigen-1. Administered subcutaneously once weekly, it decreases the activation of T lymphocytes as a primary or secondary process and interferes with the trafficking of T cells into sites of inflammation. Clinically, improvement in psoriasis can be observed as early as two to four weeks. The percent of patients experiencing a 75% reduction in PASI (PASI-75) was 27%, 44%, 47% at 12 weeks, 24 weeks, and 24 months, respectively. During the trials, the safety profile was highly favorable, with minor headaches and myalgias occurring after the initial doses. Rebound on abrupt discontinuation can be problematic for some patients and avoided by transition to an alternative therapy. Efalizumab appears to be a valuable option for patients requiring long-term control of their psoriasis. |
| | |
Authors:
|
Craig L Leonardi |
Related Documents
:
|
19692044 - Topical triamcinolone for persistent phimosis. 15141964 - Possible genotoxic risk of combined exposure to pharmaceutical coal tar and uv-b radiat... 14754644 - Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar pre... 22059904 - Functional and anatomic response of the retina and the choroid to intravitreal bevacizu... 4395004 - Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and u... 19418864 - Effect of salivary flow rate on masticatory efficiency. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Dermatologic therapy Volume: 17 ISSN: 1396-0296 ISO Abbreviation: Dermatol Ther Publication Date: 2004 |
Date Detail:
|
Created Date: 2004-09-21 Completed Date: 2005-01-24 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9700070 Medline TA: Dermatol Ther Country: Denmark |
Other Details:
|
Languages: eng Pagination: 393-400 Citation Subset: IM |
Copyright Information:
|
Copyright 2004 Blackwell Publishing, Inc. |
Affiliation:
|
Saint Louis University School of Medicine and Central Dermatology, Saint Louis, Missouri , USA. leonardi@centralderm.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
administration & dosage,
therapeutic use* Clinical Trials, Phase III as Topic Humans Psoriasis / drug therapy*, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/efalizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alefacept: a review of the literature and practical guidelines for management.
Next Document: Etanercept for the treatment of psoriasis and psoriatic arthritis.